With rigorous economic research and practical policy solutions, we focus on the issues and institutions that are critical to global development. Explore our core themes and topics to learn more about our work.
In timely and incisive analysis, our experts parse the latest development news and devise practical solutions to new and emerging challenges. Our events convene the top thinkers and doers in global development.
"The Bush administration, for example, should embrace an idea to spur vaccine development for poor countries that's popular inside the British government. The notion is that rich countries would sign a contract promising to purchase vaccines for AIDS or malaria if they are invented; that would provide an incentive for pharmaceutical giants to put research dollars to work. This approach protects intellectual property, leverages the resources of the mainly U.S.-based private sector, minimizes government meddling and costs nothing unless a vaccine is actually developed. In sum, it fits the Bush worldview perfectly. So why not applaud the Brits for their excellent leadership and get behind the idea?"
Owen's comment: Quite so. As Sebastian Mallaby's comment highlights, one of the interesting things about advance market commitments is that is has broad appeal. For those whose main concern is the fight on poverty, this is a way to engage more resources in the battle against infectious disease. For those who are sceptical of aid, this is a way to ensure that money is well spent (it costs nothing at all if it does not succeed) and to use the private sector better. This could be something on which Europe and America agree.
Last week, Gavi, the Vaccine Alliance, completed a $7.5 billion replenishment to fund its work on immunization in the world’s poorest countries between now and 2020. Gavi’s next step is to ensure that the money is used as effectively as possible to save lives and improve health.
The majority of the world’s sick live in middle-income countries (MIC) – mainly Pakistan, India, Nigeria, China and Indonesia (or PINCI), according to new data from the Institute for Health Metrics and Evaluation (IHME) at the University of Washington. Sound familiar? Andy Sumner, Denizhan Duran, and I came to the same conclusion in a 2011 paper, but we used 2004 disease burden data, which didn’t provide an up-to-date view of reality. So I was pleased to see that our findings still hold based on IHME’s 2010 Global Burden of Disease (GBD) estimates.